Becton, Dickinson and Company (NYSE:BDX) EVP Ribo Alberto Mas sold 7,463 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the sale, the executive vice president now directly owns 29,323 shares in the company, valued at $5,905,945.43. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Shares of Becton, Dickinson and Company (NYSE BDX) traded up 0.70% during midday trading on Monday, hitting $201.77. 1,558,912 shares of the stock were exchanged. The stock has a market capitalization of $45.92 billion, a price-to-earnings ratio of 58.43 and a beta of 1.05. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63. The firm’s 50 day moving average is $199.09 and its 200-day moving average is $188.17.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.35 earnings per share. On average, analysts predict that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be given a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.45%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is 83.43%.

TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/08/14/becton-dickinson-and-company-bdx-evp-sells-1503122-83-in-stock.html.

Several brokerages have commented on BDX. Cowen and Company reissued a “buy” rating and set a $230.00 price target on shares of Becton, Dickinson and in a research report on Monday. Barclays PLC reissued an “equal weight” rating and set a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Zacks Investment Research cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. Finally, BidaskClub cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Sunday, August 6th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Becton, Dickinson and currently has an average rating of “Buy” and an average price target of $195.79.

A number of hedge funds have recently made changes to their positions in BDX. BlackRock Inc. raised its stake in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after buying an additional 15,887,611 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Becton, Dickinson and by 8.5% in the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after buying an additional 1,353,780 shares in the last quarter. Winslow Capital Management LLC bought a new stake in shares of Becton, Dickinson and during the second quarter valued at approximately $225,164,000. Janus Henderson Group PLC raised its stake in shares of Becton, Dickinson and by 1,265.9% in the second quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock valued at $236,245,000 after buying an additional 1,122,191 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in shares of Becton, Dickinson and by 216.2% in the second quarter. Parametric Portfolio Associates LLC now owns 1,320,259 shares of the medical instruments supplier’s stock valued at $257,596,000 after buying an additional 902,761 shares in the last quarter. 75.57% of the stock is currently owned by institutional investors and hedge funds.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Insider Buying and Selling by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.